Grace Levy-Clarke, MD
Uveitis and Ocular Inflammatory Disease · Tampa, FLNPI 1437342847
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Sanofi at 43.4% of the total. Reporting peaked in 2019 at $15,670 and has fallen 96.9% since, to $493 in 2025.
Across 57 payments — averaging $325.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$8K
- AbbVie$8K
- ANI Pharmaceuticals, Inc.$2K
- Mallinckrodt Hospital Products Inc.$522
- Amgen$185
- Kala Pharmaceuticals, Inc.$125
- plus $269 from 7 others
Across 7 payments — averaging $56,938 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$359K
- Mallinckrodt Enterprises LLC$33K
- Gilead$5K
- Genentech, Inc.$2K
What the payments were for
- Consulting fees$6,43735%
- Speaking & faculty fees$8,76347%
- Travel & lodging$1,2287%
- Food & beverage$2,04511%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 23 | $8,045 |
| AbbVie(2 entities) | 12 | $7,813 |
| ANI Pharmaceuticals, Inc. | 1 | $1,575 |
| Mallinckrodt Hospital Products Inc. | 5 | $522 |
| Amgen | 4 | $185 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $84 |
| Mallinckrodt Enterprises LLC | 3 | $72 |
| Gilead | 2 | $40 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $27 |
| Genentech, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Alcon | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humira$7,407
- DISEASE STATE$7,317
- PURIFIED CORTROPHIN GEL$1,575
- ACTHAR$471
- OZURDEX$134
- INVELTYS$125
How this compares
Too few uveitis and ocular inflammatory disease providers in Floridato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 24 | $1,043 |
| ValacyclovirValacyclovir Hcl | 11 | $747 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $414 |
| Prednisone | 33 | $313 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 19 | $236 |
| Brimonidine Tartrate | 12 | $142 |
| Methylprednisolone | 14 | $101 |
| Latanoprost | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other uveitis and ocular inflammatory disease in Tampa
- Maura di NicolaMiami$26K
- Stephanie Llop QuintanaMiami$2K
- Henry LederJacksonville$1K
- Raul Ruiz LozanoMiami$304
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.